All companies
Visit website
DEVERRA THERAPEUTICS
OperatingDeverra Therapeutics, Inc.
Healthcare · Biotech · Founded 2020
Biotech company committed to providing universal donor treatments
Post-money valuation ⓘ
$60.8M
As of Sep 2024 · from Deverra Therapeutics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$971,018
Across 1 round since 2024
Latest share price
$2.09
Deverra Therapeutics Common Stock 1 offering price
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its source$0
−$9.0M
2021
$0
−$6.9M
2022
$1.7M
$1.7M
2023
$3.9M
−$3.7M
2024
$697K
−$1.5M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$1,677,259
$3,879,188
$696,727
Cost of goods sold
$8,599,659
$0
$1,677,259
$3,879,188
$696,727
Gross margin
—
—
0%
0%
0%
Net income
-$9,035,503
-$6,899,704
$1,672,096
-$3,718,063
-$1,523,035
Taxes paid
$0
$0
$0
$72,893
$29,694
Balance sheet
Cash
$1,795,952
$78,636
$264,595
$115
$1,612
Accounts receivable
$0
$450
$428,989
$0
$0
Total assets
$4,845,249
$4,845,249
$7,153,624
$11,309,047
$10,077,334
Short-term debt
$2,684,474
$7,448,108
$3,954,051
$1,690,073
$1,435,000
Long-term debt
$926,203
$256,667
$0
$0
$102,917
Total liabilities
$3,610,677
$7,704,775
$3,954,051
$1,690,073
$1,537,917
Other
Headcount
—
12
12
12
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$60.8M
post-money
Deverra Therapeutics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $971K / $1.2MInvestors 338Post-money $60.8M
Reg CF annual-report compliance
Compliant
Filed 3 of 3 annual reports (FY2023–FY2025)
338 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001822782Share price $2.09
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.